Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
[HTML][HTML] Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation–positive non–small-cell lung cancer treated …
M Takeda, I Okamoto, K Nakagawa - Journal of Thoracic Oncology, 2014 - Elsevier
Introduction: Somatic mutations in the epidermal growth factor receptor gene (EGFR) are
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
associated with a marked therapeutic response to EGFR–tyrosine kinase inhibitors (TKIs) in …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
[HTML][HTML] Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on …
YL Wu, WZ Zhong, LY Li, XT Zhang, L Zhang… - Journal of Thoracic …, 2007 - Elsevier
Background Convincing data on epidermal growth factor receptor (EGFR) mutations in
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …
Chinese patients with non-small-cell lung cancer (NSCLC) remain limited. We investigated …
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non–small-cell lung cancer with epidermal growth factor receptor gene …
A Inoue, T Suzuki, T Fukuhara, M Maemondo… - Journal of Clinical …, 2006 - ascopubs.org
Purpose This study was undertaken to investigate the efficacy and the feasibility of gefitinib
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
for chemotherapy-naïve patients with advanced non–small-cell lung cancer (NSCLC) …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
ZY Chen, WZ Zhong, XC Zhang, J Su, XN Yang… - The …, 2012 - academic.oup.com
Background. Non-small cell lung cancer patients with epidermal growth factor receptor
(EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor …
(EGFR) mutations have mixed responses to tyrosine kinase inhibitors (TKIs). Intertumor …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell, TJ Lynch, SM Haserlat, PL Harris… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
相关搜索
- lung cancer egfr mutation
- gefitinib for the treatment egfr mutations
- gefitinib treatment relative abundance
- egfr mutations relative abundance
- lung cancer gefitinib treatment
- lung cancer relative abundance
- lung cancer tumor response
- lung cancer growth factor
- tumor response egfr mutation
- survival outcome egfr mutation
- chinese patients egfr mutation
- lung cancer survival outcome
- lung cancer chinese patients
- gefitinib for the treatment previous chemotherapy
- shrinkage pattern egfr mutation
- lung adenocarcinomas mutation heterogeneity